Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers

Hussain, Salman; Jamali, Mohammad Chand; Habib, Anwar; Hussain, Sarfaraj; Akhtar, Mohd; Najmi, Abul Kalam

doi:10.1016/j.cegh.2020.05.016

Cited by 71 publications

(61 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Controlled blood pressure and controlled blood glucose level do not always prevent this complication Genetic factors thought to be involved. 2,5,22 Our research reported the older age, blood pressure, and TGF-ß genetic variant were associated with decreased renal function in T2DM.…”

Section: Discussionmentioning

confidence: 77%

Genetic variant of TGF-ß associated with decreased renal function in type II diabetes mellitus patient: single center pilot study in Indonesia

Puspasari

Elfiani

Tarawifa

et al. 2021

JMedSci

View full text Add to dashboard Cite

The interaction between genetic factors, blood glucose and hypertension plays a role in the onset of diabetic kidney disease (DKD) in type II diabetes mellitus (T2DM). Genetic variation of TGF-ß1 is associated with renal complication in T2DM with varying results between ethnicities. The Jambi Malay ethnic, which is the majority ethnic in Jambi Province, is an area that reports an increased prevalence of T2DM with DKD as the most frequent microvascular complications. In addition, previous study reported controlling blood glucose not associated with DKD indicating genetic may have play a role in DKD in this population. Studies related to genetic variation and decreased kidney function in T2DM patients has never been performed in this ethnic group. This study aimed to investigate the role of TGF-ß genetic variation as risk factor for decreased renal function in T2DM patients from Jambi Malay ethnicity. We conducted a cross sectional study involving 70 patients with T2DM. The inclusion criteria for renal complication based on a decrease in the glomerular filtration rate (GFR) of less than 60 mL/min/1.73. The genotyping method used was amplification refractory mutation system polymerase chain reaction (ARMS-PCR) for TGF-β1 rs1800470 T/C. Bivariate and multivariate analysis was performed to analyze phenotype and genotype association. The result of bivariate analysis showed T2DM patients with genotype CT (p:0.006; OR:0.125; 95% CI:0.027-0.575) and CC (p:0.007; OR:0.104; 95% CI:0.020-0.546) or C allele carrier (p:0.003; OR:0.117; 95% CI:0.027-0.500) had lower risk for decreased renal function than TT genotype. Multivariate analysis that included blood pressure and age variables showed the same finding for CT (p:0.007; OR:0.086; 95% CI:0.014-0.508) and CC genotype (p:0.022; OR:0.115; 95% CI:0.018-0.731). It is concluded from this study that T2DM patients with genotype CT, CC and carrier allele C have a lower risk for suffering kidney complications than genotype TT.

show abstract

Section: Discussionmentioning

confidence: 77%

Genetic variant of TGF-ß associated with decreased renal function in type II diabetes mellitus patient: single center pilot study in Indonesia

Puspasari

Elfiani

Tarawifa

et al. 2021

JMedSci

View full text Add to dashboard Cite

show abstract

“…Diabetic nephropathy (DN) is a common microvascular complication of diabetes and a major cause of end-stage renal disease worldwide [2,20]. Traditional techniques, such as the histological assessment of collagen deposition and quantification of serum/urine biomarkers (e.g., creatinine, blood urea nitrogen (BUN), albumin, and cytokines), are the most commonly used to diagnose kidney disorders [3].…”

Section: Discussionmentioning

confidence: 99%

“…Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is the progressive development of renal insufficiency induced by the diabetic milieu [1]. Approximately 40% of patients diagnosed with either type 1 or type 2 diabetes develop DN, and this number is projected to increase dramatically with the increasing trend of diabetes worldwide [2,3]. Currently, DN research relies on traditional diagnostic techniques, such as the histological assessment of collagen deposition and quantification of serum/urine biomarkers (e.g., creatinine, blood urea nitrogen (BUN), albumin, and cytokines) to confirm kidney disorders [3].…”

Section: Introductionmentioning

confidence: 99%

Serum Amyloid A3 Promoter-Driven Luciferase Activity Enables Visualization of Diabetic Kidney Disease

Saliu

Yazawa

Hashimoto

et al. 2022

IJMS

View full text Add to dashboard Cite

The early detection of diabetic nephropathy (DN) in mice is necessary for the development of drugs and functional foods. The purpose of this study was to identify genes that are significantly upregulated in the early stage of DN progression and develop a novel model to non-invasively monitor disease progression within living animals using in vivo imaging technology. Streptozotocin (STZ) treatment has been widely used as a DN model; however, it also exhibits direct cytotoxicity to the kidneys. As it is important to distinguish between DN-related and STZ-induced nephropathy, in this study, we compared renal responses induced by the diabetic milieu with two types of STZ models: multiple low-dose STZ injections with a high-fat diet and two moderate-dose STZ injections to induce DN. We found 221 genes whose expression was significantly altered during DN development in both models and identified serum amyloid A3 (Saa3) as a candidate gene. Next, we applied the Saa3 promoter-driven luciferase reporter (Saa3-promoter luc mice) to these two STZ models and performed in vivo bioluminescent imaging to monitor the progression of renal pathology. In this study, to further exclude the possibility that the in vivo bioluminescence signal is related to renal cytotoxicity by STZ treatment, we injected insulin into Saa3-promoter luc mice and showed that insulin treatment could downregulate renal inflammatory responses with a decreased signal intensity of in vivo bioluminescence imaging. These results strongly suggest that Saa3 promoter activity is a potent non-invasive indicator that can be used to monitor DN progression and explore therapeutic agents and functional foods.

show abstract

“…DKD develops in approximately 40% of patients with type 2 diabetes (T2D) and 30% of patients with type 1 diabetes (T1D) and is the leading cause of chronic kidney disease (CKD) and end-stage renal disease [1,2]. The mortality risk associated with DKD has increased by 31.1% and increases with worsening disease severity [3]. It is reported that DKD affects males and females equally and it rarely develops before 10 years duration of T1D [4].…”

Section: Introductionmentioning

confidence: 99%

The Effect of SGLT2 Inhibition on Diabetic Kidney Disease in a Model of Diabetic Retinopathy

et al. 2022

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is a chronic disorder characterized by elevated urine albumin excretion, reduced glomerular filtration rate, or both. At present, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are the standard care for the treatment of DKD, resulting in improved outcomes. However, alternative treatments may be required because although the standard treatments have been found to slow the progression of DKD, they have not been found to halt the disease. In the past decade, sodium glucose co-transporter 2 (SGLT2) inhibitors have been widely researched in the area of cardiovascular disease and diabetes and have been shown to improve cardiovascular outcomes. SGLT2 inhibitors including canagliflozin and dapagliflozin have been shown to slow the progression of kidney disease. There is currently an omission of literature where three SGLT2 inhibitors have been simultaneously compared in a rodent diabetic model. After diabetic Akimba mice were treated with SGLT2 inhibitors for 8 weeks, there was not only a beneficial impact on the pancreas, signified by an increase in the islet mass and increased plasma insulin levels, but also on the kidneys, signified by a reduction in average kidney to body weight ratio and improvement in renal histology. These findings suggest that SGLT2 inhibition promotes improvement in both pancreatic and kidney health.

show abstract

Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers

Cited by 71 publications

References 68 publications

Genetic variant of TGF-ß associated with decreased renal function in type II diabetes mellitus patient: single center pilot study in Indonesia

Genetic variant of TGF-ß associated with decreased renal function in type II diabetes mellitus patient: single center pilot study in Indonesia

Serum Amyloid A3 Promoter-Driven Luciferase Activity Enables Visualization of Diabetic Kidney Disease

The Effect of SGLT2 Inhibition on Diabetic Kidney Disease in a Model of Diabetic Retinopathy

Contact Info

Product

Resources

About